IRL-201104 is under clinical development by Revolo Biotherapeutics and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase transition ...
A new study has shown that people who have asthma or sniffling caused by allergies also carry a different set of fungi in their nasal cavities compared to | Cell And Molecular Biology ...